Video Interview—Johnson & Johnson Innovation

Rowan Chapman talks from this year's ASCO about what innovation means to J&J.

As part of our new video interview series, we sat down with Rowan Chapman, head of J&J Innovation California, to get her thoughts on what the big pharma company wants to see from its potential life science partners.

Chapman explained how J&J Innovation is the “Big Red Door” when it comes to biomedical research partnering, and the broad strokes the unit uses when it comes to nurturing and incubating talent.

She also discussed the Next Big Thing for J&J—disease prevention, rather than just treatment—and said that despite the risks being higher in biomedical research than ever before, she never sees a time when entrepreneurs in healthcare will stop striving to create new medicines.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.


Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.